Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
about
Androgen deprivation therapy in the treatment of advanced prostate cancerIntermittent versus continuous androgen suppression therapy: do we have consensus yet?A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.Hormone therapy in the management of prostate cancer: evidence-based approachesOptimizing outcomes and quality of life in the hormonal treatment of prostate cancer.The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight.Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.Leuprorelin depot injection: patient considerations in the management of prostatic cancerAdverse effects of androgen deprivation therapy for prostate cancer: prevention and managementType I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy.Management of anaemia in prostate cancer.Pharmacotherapeutic management of locally advanced prostate cancer: current status.Safety and tolerability of intermittent androgen deprivation therapy: a literature review.The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer.Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial.
P2860
Q24676531-F2066B7B-0844-40D0-BE40-B4E10A388F6CQ34111614-667F3F10-5E7E-45D5-A40E-3460FB617CC8Q35034020-80DFF6DF-9E59-4A69-9708-A2D8F44FD79FQ35076432-E7DDCF87-3D3F-4E35-AA57-C5196FCF46D5Q36432836-FD6CE02A-E340-41F1-A5F7-CE21A85BC0EFQ36710270-92A00042-9348-4E8F-AC19-AA82EA265BE6Q36710276-25FB8568-5014-4164-9084-DC20CCB88268Q36823588-7DA38258-1A79-4D21-B65A-E6740A62AF77Q37105407-354AF8CE-F50E-4274-A2AF-EEB4FB6F9FADQ37137452-E34C26A3-0D12-40C6-80D3-5A0FBF95F59BQ37283578-E0CC5A0B-FD0D-48B8-8D66-CD039F5DB139Q37622931-752A3F85-5D53-454D-9FDB-651575925044Q37888666-0DB1ABFE-6DA9-4B69-853D-76A61C6EDB0CQ37995670-E896A34C-1EF4-4C5C-8A2C-E57CE0399427Q38353806-80886854-A85E-4066-B62D-BA489C24B74BQ43509250-0CDA964E-FD1C-4958-B3DE-F2EF90E6F4A4Q46774758-6ABE2411-4C89-44F7-B3F0-9AE142CB3147
P2860
Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Long-term side-effects of inte ...... : results of a phase II study.
@en
Long-term side-effects of inte ...... : results of a phase II study.
@nl
type
label
Long-term side-effects of inte ...... : results of a phase II study.
@en
Long-term side-effects of inte ...... : results of a phase II study.
@nl
prefLabel
Long-term side-effects of inte ...... : results of a phase II study.
@en
Long-term side-effects of inte ...... : results of a phase II study.
@nl
P2093
P2860
P1433
P1476
Long-term side-effects of inte ...... : results of a phase II study.
@en
P2093
Juanita Crook
Roanne Segal
Shawn Malone
Simone Dahrouge
P2860
P304
P356
10.1111/J.1464-410X.2005.05676.X
P577
2005-09-01T00:00:00Z